Helicos BioSciences Corp. confirmed Tuesday it continues to work with an investment bank to explore “strategic alternatives” and is engaged in discussions with multiple parties to potentially advance its genetic-sequencing technologies.

The Cambridge, Mass.-based company, which has seen its cash position shrink amid a string of losses and limited revenue generation, did not disclose the nature of those discussions nor did it name the parties involved. It has retained Thomas Weisel Partners, which has offices in Boston and other major cities globally, to manage those negotiations.

The update comes amid several operating and sales developments for the 6-year-old company. Helicos said in the quarter ended Sept. 30, it more than doubled its sales .